J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes

Johnson & Johnson cites the 2005 switch to the ASP-plus 6% reimbursement model among its reasons for optimism despite Procrit’s recent performance. Aranesp is gaining on J&J brand; Procrit market share slipped to 61% in second quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet